Literature DB >> 22393538

Modeling Parkinson's disease in primates: The MPTP model.

Gregory Porras1, Qin Li, Erwan Bezard.   

Abstract

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate models of Parkinson's disease (PD) reproduce most, although not all, of the clinical and pathological hallmarks of PD. The present contribution presents the possibilities offered by the MPTP monkey models of PD to readers with minimal knowledge of PD, emphasizing the diversity of species, route and regimen of administration, symptoms and pathological features. Readers would eventually find out that there is not a single MPTP monkey model of PD but instead MPTP monkey models of PD, each addressing a specific experimental need.

Entities:  

Mesh:

Year:  2012        PMID: 22393538      PMCID: PMC3282499          DOI: 10.1101/cshperspect.a009308

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  70 in total

1.  Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

Authors:  Brian Henry; Susan Duty; Susan H Fox; Alan R Crossman; Jonathan M Brotchie
Journal:  Exp Neurol       Date:  2003-10       Impact factor: 5.330

2.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

3.  Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.

Authors:  Nancy Bélanger; Laurent Grégoire; Abdallah Hadj Tahar; Paul J Bédard
Journal:  Mov Disord       Date:  2003-12       Impact factor: 10.338

4.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

Authors:  J W Langston; L S Forno; C S Rebert; I Irwin
Journal:  Brain Res       Date:  1984-02-06       Impact factor: 3.252

5.  MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.

Authors:  D Doudet; C Gross; P Lebrun-Grandie; B Bioulac
Journal:  Brain Res       Date:  1985-05-27       Impact factor: 3.252

6.  Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.

Authors:  Erwan Bezard; Michael P Hill; Alan R Crossman; Jonathan M Brotchie; Anne Michel; Renee Grimée; Henrik Klitgaard
Journal:  Eur J Pharmacol       Date:  2004-02-06       Impact factor: 4.432

7.  Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.

Authors:  C C Chiueh; S P Markey; R S Burns; J N Johannessen; D M Jacobowitz; I J Kopin
Journal:  Psychopharmacol Bull       Date:  1984

Review 8.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

9.  3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.

Authors:  Mahmoud M Iravani; Michael J Jackson; Mikko Kuoppamäki; Lance A Smith; Peter Jenner
Journal:  J Neurosci       Date:  2003-10-08       Impact factor: 6.167

10.  Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys.

Authors:  Caroline Jan; Mathias Pessiglione; Léon Tremblay; Dominique Tandé; Etienne C Hirsch; Chantal François
Journal:  Eur J Neurosci       Date:  2003-10       Impact factor: 3.386

View more
  50 in total

1.  Network Structure and Function in Parkinson's Disease.

Authors:  Ji Hyun Ko; Phoebe G Spetsieris; David Eidelberg
Journal:  Cereb Cortex       Date:  2018-12-01       Impact factor: 5.357

Review 2.  The endometrium as a source of mesenchymal stem cells for regenerative medicine.

Authors:  Levent Mutlu; Demetra Hufnagel; Hugh S Taylor
Journal:  Biol Reprod       Date:  2015-04-22       Impact factor: 4.285

3.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

Review 4.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

5.  Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.

Authors:  Mrittika Chattopadhyay; Anindya Roy Chowdhury; Ting Feng; Charles-Antoine Assenmacher; Enrico Radaelli; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2019-05-20       Impact factor: 5.157

Review 6.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

7.  Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Authors:  Kimberley A Phillips; Corinna N Ross; Jennifer Spross; Catherine J Cheng; Alyssa Izquierdo; K C Biju; Cang Chen; Senlin Li; Suzette D Tardif
Journal:  Behav Brain Res       Date:  2017-02-17       Impact factor: 3.332

8.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

Review 9.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

10.  Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism.

Authors:  Naoki Inoue; Sae Ogura; Atsushi Kasai; Takanobu Nakazawa; Kazuya Ikeda; Shintaro Higashi; Ayako Isotani; Kousuke Baba; Hideki Mochizuki; Harutoshi Fujimura; Yukio Ago; Atsuko Hayata-Takano; Kaoru Seiriki; Yusuke Shintani; Norihito Shintani; Hitoshi Hashimoto
Journal:  EMBO Rep       Date:  2018-01-25       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.